Indaptus Therapeutics Inc
Change company Symbol lookup
Select an option...
INDP Indaptus Therapeutics Inc
FUSN Fusion Pharmaceuticals Inc
RDUS Schnitzer Steel Industries Inc
ALEC Alector Inc
LZM Lifezone Metals Ltd
LMRMF Lomiko Metals Inc
SOXL Direxion Daily Semiconductor Bull 3X Shares
OXSQ Oxford Square Capital Corp
BAER Bridger Aerospace Group Holdings Inc
CMRA Comera Life Sciences Holdings Inc

Health Care : Biotechnology |
Company profile

Indaptus Therapeutics, Inc. is a clinical biotechnology company. The Company is focused on enhancing and expanding curative cancer immunotherapy for patients with unresectable or metastatic solid tumors and lymphomas. It designs its approach by targeting specific tumor or viral antigens. Its lead candidate, Decoy20, through pre-clinical development. Its platform is based on the hypothesis that require anti-tumor immunotherapy to activate both innate and adaptive cellular immunity in both tumors and immune organs. Its approach uses multi-targeted package of bacterial pathogen-associated molecular patterns (PAMPs), in the form of attenuated and killed, intact but non-pathogenic bacteria delivered intravenously. Its intravenous therapeutic candidates target the liver, spleen, and leaky vasculature of tumors, producing immune activation in an immune organ, as well as a common site for primary and metastatic cancer and hepatitis B virus (HBV) infection.

Closing Price
Day's Change
-0.25 (-9.23%)
B/A Size
Day's High
Day's Low

10-day average volume:

Okta stock plunges, CEO sees tough times ahead even as earnings forecast moves higher

4:09 pm ET May 31, 2023 (MarketWatch)

By Wallace Witkowski

'We raised the guidance but we actually think the macro condition could get worse,' CEO tells MarketWatch in interview

Okta Inc. shares plunged in the extended session Wednesday after the identity-management software company raised expectations for the months ahead even while its chief executive warned macroeconomic conditions could worsen.

In an interview with MarketWatch ahead of the company's conference call, Okta (OKTA)Chief Executive Todd McKinnon, a company co-founder, said that even while increasing his annual forecast, he sees a tougher business environment ahead.

"We raised the guidance but we actually think the macro condition could get worse, so we're being pretty conservative with our guidance," McKinnon told MarketWatch.

Shares dove more than 10% in after-hours, following a 0.9% gain to close the regular session at $90.90.

For the second quarter, Okta executives forecast adjusted earnings of 21 cents to 22 cents a share on revenue of $533 million to $535 million, while the Street expected 16 cents a share on revenue of $528.4 million, according to FactSet. Okta also hiked its outlook for the year, forecasting adjusted earnings of 88 cents to 93 cents a share on revenue of $2.18 billion to $2.19 billion, up from a previous forecast of 74 cents to 79 cents a share on revenue of $2.16 billion to $2.17 billion.

McKinnon listed concerns about interest rates, inflation and business spending being scrutinized more so than fallout from the failure of Silicon Valley Bank. Many young software companies that relied upon upsells and cross-sells faced a tougher time closing deals after the failure of many startups' favorite bank.

Read: Cybersecurity stocks are getting battered. Here's how the Silicon Valley Bank failure is to blame.

Okta reported a first-quarter loss of $119 million, or 74 cents a share, compared with a loss of $243 million, or $1.56 a share, in the year-earlier period. After adjusting for stock-based compensation expenses and other items, the company reported earnings of 22 cents a share, versus a loss of 27 cents a share a year before. Revenue rose to $518 million from $414.9 million in the year-ago quarter.

Analysts had forecast adjusted earnings of 12 cents a share on revenue of $511 million. That was based on the company's forecast of 11 cents or 12 cents a share on revenue of $509 million to $511 million.

From the archives (November 2022): Okta CEO promises profit for all of next year: 'The problem was never that we didn't have talented sales people'

-Wallace Witkowski

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.


(END) Dow Jones Newswires

May 31, 2023 16:09 ET (20:09 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.